FOXO4-DRISenolytic PeptideSafety Rating 3/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 10mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Ascension PeptidesBest $/mgCOA ✓ · 3P | $100.00 | $10.00 | Apr 16, 2026 | Buy → |
| PeptiraCOA ✓ · 3P | $166.00 | $16.60 | May 14, 2026 | Buy → |
| SomaChemsCOA ✓ · 3P | $179.99 | $18.00 | May 14, 2026 | Buy → |
| Modern AminosCOA ✓ · 3P | $218.00 | $21.80 | May 14, 2026 | Buy → |
| Core PeptidesCOA ✓ · 3P | $235.00 | $23.50 | Apr 16, 2026 | Buy → |
Overview
About FOXO4-DRI
Mechanism of action
D-amino acid retro-inverso FOXO4 peptide; disrupts FOXO4-p53 interaction in senescent cells; triggers selective apoptosis of senescent cells (senolytic); clears 'zombie cells' without harming normal cells.
Safety profile
Potential weight loss, lethargy in animal models. Long-term human data very limited. Theoretical risk: removal of beneficial senescent cells in wound healing. · Experimental senolytic that works by disrupting the FOXO4–p53 interaction. p53 is the master tumor-suppressor protein — modulating it carries serious theoretical oncogenic risk, and there is zero human safety data. Animal data only.
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops FOXO4-DRI below your target.
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Experimental senolytic with limited human data. Selectively targets senescent cells in animal studies.
Related pages
More on FOXO4-DRI
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- FOXO4-DRI is a D-amino acid retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells; in normal senescent cells FOXO4 sequesters p53 in nuclear PML bodies, preventing its pro-apoptotic function — FOXO4-DRI competitively displaces this interaction, causing p53 nuclear exclusion and activation of apoptosis selectively in senescent cells.
- The landmark 2017 Cell paper demonstrated that FOXO4-DRI restored fitness, fur density, and renal function in both fast-aging XpdTTD/TTD mice and naturally aged mice, and reduced doxorubicin-induced chemotoxicity in a senescence-dependent manner — providing the first in vivo proof that selective senescent cell elimination with a peptide reverses multiple aging-associated phenotypes.